Sigachi Industries Valuation

Is 543389 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 543389 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 543389 (₹51.04) is trading above our estimate of fair value (₹1.84)

Significantly Below Fair Value: 543389 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 543389?

Key metric: As 543389 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 543389. This is calculated by dividing 543389's market cap by their current earnings.
What is 543389's PE Ratio?
PE Ratio	25.4x
Earnings	₹660.99m
Market Cap	₹16.78b

543389 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.1x
Enterprise Value/EBITDA	23x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 543389's PE Ratio compare to its peers?

The above table shows the PE ratio for 543389 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	39.6x
BETA Beta Drugs	50.3x	n/a	₹20.6b
524470 Syncom Formulations (India)	57.5x	n/a	₹19.1b
SMSPHARMA SMS Pharmaceuticals	37.2x	n/a	₹22.1b
531633 Lincoln Pharmaceuticals	13.2x	n/a	₹12.8b
543389 Sigachi Industries	25.4x	n/a	₹16.8b

Price-To-Earnings vs Peers: 543389 is good value based on its Price-To-Earnings Ratio (25.4x) compared to the peer average (39.6x).

Price to Earnings Ratio vs Industry

How does 543389's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
INDSWFTLAB Ind-Swift Laboratories	1.5x	n/a	US$64.93m
524652 Ind-Swift	2.1x	n/a	US$13.44m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 543389 is good value based on its Price-To-Earnings Ratio (25.4x) compared to the Indian Pharmaceuticals industry average (33.7x).

Price to Earnings Ratio vs Fair Ratio

What is 543389's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

543389 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	25.4x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 543389's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

-45.9%

Colinz Laboratories

₹145.8m

Manufactures, markets, and trades in pharmaceutical formulations in India.

531210

₹57.89

10.2%

39.8%

Novartis India

₹26.1b

Operates as a healthcare company in India.

500672

₹1,055.70

3.1%

47.8%